TrialBlood cancer journal2021

A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia.

Joshua F Zeidner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.